Whole-exosome sequencing assessment of baseline and relapsed tumors from four patients with melanoma who developed resistance to anti-PD-1 therapy after the initial response identified an acquired homozygous truncating mutation in the gene encoding B2M at relapse in one patient (64). The gene discussed is PDCD1; the disease is melanoma.